- Home
- ARGX vs MSCI Comparison
ARGX vs MSCI Comparison
Compare ARGX & MSCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARGX
- MSCI
- Stock Information
- Founded
- ARGX 2008
- MSCI 1998
- Country
- ARGX Netherlands
- MSCI United States
- Employees
- ARGX N/A
- MSCI N/A
- Industry
- ARGX Biotechnology: Biological Products (No Diagnostic Substances)
- MSCI Business Services
- Sector
- ARGX Health Care
- MSCI Consumer Discretionary
- Exchange
- ARGX Nasdaq
- MSCI Nasdaq
- Market Cap
- ARGX 40.4B
- MSCI 44.5B
- IPO Year
- ARGX 2017
- MSCI 2007
- Fundamental
- Price
- ARGX $591.87
- MSCI $565.69
- Analyst Decision
- ARGX Strong Buy
- MSCI Strong Buy
- Analyst Count
- ARGX 20
- MSCI 14
- Target Price
- ARGX $682.00
- MSCI $649.23
- AVG Volume (30 Days)
- ARGX 314.1K
- MSCI 564.1K
- Earning Date
- ARGX 05-08-2025
- MSCI 04-22-2025
- Dividend Yield
- ARGX N/A
- MSCI 1.27%
- EPS Growth
- ARGX N/A
- MSCI N/A
- EPS
- ARGX 12.78
- MSCI 14.05
- Revenue
- ARGX $2,248,205,000.00
- MSCI $2,856,128,000.00
- Revenue This Year
- ARGX $57.86
- MSCI $10.85
- Revenue Next Year
- ARGX $31.90
- MSCI $8.97
- P/E Ratio
- ARGX $43.78
- MSCI $40.26
- Revenue Growth
- ARGX 77.22
- MSCI 12.94
- 52 Week Low
- ARGX $352.77
- MSCI $439.95
- 52 Week High
- ARGX $678.21
- MSCI $642.45
- Technical
- Relative Strength Index (RSI)
- ARGX 42.34
- MSCI 48.45
- Support Level
- ARGX $582.07
- MSCI $564.20
- Resistance Level
- ARGX $598.06
- MSCI $578.93
- Average True Range (ATR)
- ARGX 13.05
- MSCI 11.44
- MACD
- ARGX -0.35
- MSCI 1.42
- Stochastic Oscillator
- ARGX 33.69
- MSCI 68.33
About ARGX argenx SE
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.
About MSCI MSCI Inc.
MSCI has described its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1.7 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In private assets, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.